Cargando…
TOCILIZUMAB- A TREATMENT OPTION FOR TORSADES DE POINTES IN COVID-19 PATIENTS
Autores principales: | Anwaar, Muhammad Faraz, Kazmi, Sana, Khosla, Jagjit, Gujju, Veena, Agarwal, Siddharth, Krishan, Satyam, Khan, Jehanzeb, Akkus, Nuri Ilker |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Cardiology Foundation. Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982942/ http://dx.doi.org/10.1016/S0735-1097(23)04354-1 |
Ejemplares similares
-
Torsade de Pointes Induced by Hypokalemia from Imipenem and Piperacillin
por: Kumar, Varun, et al.
Publicado: (2017) -
Ceftriaxone/hydroxychloroquine/tocilizumab: QT prolongation, torsade-de-pointes and off label use: case report
Publicado: (2020) -
COVID-19 INDUCED CARDIOMYOPATHY SUCCESSFULLY TREATED WITH TOCILIZUMAB
por: Fakhra, Sadaf, et al.
Publicado: (2022) -
A tale of 2 torsades: How to approach a patient with torsades de pointes and distinguish between classical and pseudo–torsades de pointes
por: Scheinman, Melvin, et al.
Publicado: (2022) -
Ondansetron induced torsades de pointes
por: Patel, Eshan, et al.
Publicado: (2019)